Network meta-analysis of randomised trials (17 for exacerbations, 22 for safety) in severe asthma: in the fully adjusted model depemokimab reduced annualised exacerbations vs placebo, with no significant difference vs other biologics; adverse event odds were similar.
Meta-analysisn = 22 trials
Bourdin et al. Depemokimab reduces asthma exacerbations similarly to other biologics